辉瑞（PFE）今日盘前股价大跌5.06%，引发了市场的广泛关注。
消息面上，辉瑞最新公布的第四季度财报显示，公司营收同比减少，并意外录得净亏损，主要由于其新冠疫苗和抗病毒药物的市场需求持续萎缩。同时，公司发布的2026年业绩指引也反映出“最惠国”药品定价政策与特朗普处方药政策预计带来的双重不利影响，给未来盈利前景蒙上阴影。
此外，公司一款实验性药物在临床试验的周剂量阶段，有参与者因不良事件而中止治疗，这可能也加剧了投资者对研发管线安全性的担忧。多重利空因素叠加，导致股价在盘前交易时段承压大幅下挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.